MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group’s 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.
The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here.
About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.
Contact:
Jaclyn Jaffe
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com
DiscoverSTEM Celebrates Innovation with Award-Winning Solutions from Youth Innovators Across the USA and UAE.Dallas, Texas--(Newsfile…
DALLAS, TX / ACCESSWIRE / October 9, 2024 / Formula Wellness, a leading innovator in…
NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Report with the AI impact on market trends…
NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Report with market evolution powered by AI -…
The medical software company closes the care gap in reproductive health by providing clinical decision…
Info-Tech Research Group's new blueprint outlines strategic approaches for healthcare IT leaders to effectively navigate…